AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development
Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition